Compare Abeona Therapeutics Inc (ABEO) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Uranium Energy Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Uranium Energy Corp trades at $11.38 (market cap $5.67B). The key difference: Uranium Energy Corp is far larger — about 13.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | UEC | |
|---|---|---|
Market Cap | $421.19M | $5.67B |
Sector | Health | Energy |
52-Week High | $7.45 | $20.14 |
52-Week Low | $4.17 | $9.04 |
Enterprise Value | $276.10M | $5.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Uranium Energy Corp (UEC) trades at $11.45, up 0.62% today, with a bullish technical signal supported by moving averages. The company shows significant financial challenges with a net income margin of -513.24% and negative cash flow from operations, though it maintains strong analyst support with 87.5% buy ratings. Recent news highlights insider selling but also optimistic long-term nuclear energy prospects.
UEC presents high-risk, high-reward potential driven by nuclear energy tailwinds, but faces substantial execution risks amid persistent losses and premium valuation. The stock's outlook hinges on production ramp-up success and uranium price movements, with current financials indicating cautious near-term investor sentiment despite bullish analyst consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
